Claritas Pharmaceuticals, Inc. engages in the development of next generation cannabinoid therapeutics. The company is headquartered in San Rafael California, California. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The firm has leased a laboratory, office, and archival space in Beverly, Massachusetts.
Follow-Up Questions
¿Quién es el CEO de Claritas Pharmaceuticals Inc?
Mr. Robert Farrell es el Chairman of the Board de Claritas Pharmaceuticals Inc, se unió a la empresa desde 2016.
¿Qué tal es el rendimiento del precio de la acción CLAZF?
El precio actual de CLAZF es de $0, ha decreased un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Claritas Pharmaceuticals Inc?
Claritas Pharmaceuticals Inc pertenece a la industria Pharmaceuticals y el sector es Health Care
¿Cuál es la capitalización bursátil de Claritas Pharmaceuticals Inc?
La capitalización bursátil actual de Claritas Pharmaceuticals Inc es $0
